Biotech News- 2/9/15 to 2/13/15

Achillion Pharmaceuticals (ACHN) Shares of Achillion gained 7% on 2/9/15 last week when it had announced that it had achieved a 100% SVR12 in a phase 2 trial treating patients with the genotype 1 version of the Hepatitis C virus — HCV. The trial tested for the primary objective of patients being able to achieve a … Read more